Richard W. Tothill

9.5k total citations · 1 hit paper
63 papers, 3.8k citations indexed

About

Richard W. Tothill is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Richard W. Tothill has authored 63 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 27 papers in Cancer Research and 22 papers in Molecular Biology. Recurrent topics in Richard W. Tothill's work include Cancer Diagnosis and Treatment (17 papers), Cancer Genomics and Diagnostics (14 papers) and Tumors and Oncological Cases (11 papers). Richard W. Tothill is often cited by papers focused on Cancer Diagnosis and Treatment (17 papers), Cancer Genomics and Diagnostics (14 papers) and Tumors and Oncological Cases (11 papers). Richard W. Tothill collaborates with scholars based in Australia, United States and United Kingdom. Richard W. Tothill's co-authors include David D.L. Bowtell, Maria Doyle, Cliff Meldrum, Izhak Haviv, Stephen B. Fox, Joshy George, Jason Li, Rodney J. Hicks, Anna DeFazio and Sián Fereday and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Richard W. Tothill

61 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

2008 1.0k citations Richard W. Tothill, Anna V. Tinker et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard W. Tothill Australia	30	1.7k	1.4k	1.3k	597	516	63	3.8k
Izhak Haviv Australia	29	2.3k 1.3×	1.2k 0.8×	1.3k 1.0×	660 1.1×	316 0.6×	56	4.4k
Gulisa Turashvili Canada	29	1.9k 1.1×	1.4k 1.0×	1.2k 1.0×	301 0.5×	386 0.7×	109	3.9k
Reinhard Horvat Austria	40	1.8k 1.1×	1.0k 0.7×	1.4k 1.1×	450 0.8×	383 0.7×	106	4.2k
Bjørn Risberg Norway	41	1.8k 1.0×	877 0.6×	1.4k 1.1×	788 1.3×	451 0.9×	131	4.6k
Simona Losito Italy	34	1.2k 0.7×	562 0.4×	983 0.8×	562 0.9×	339 0.7×	113	3.1k
Josep Castellví Spain	33	1.7k 1.0×	838 0.6×	1.0k 0.8×	199 0.3×	389 0.8×	109	3.6k
Tom van Wezel Netherlands	42	2.4k 1.4×	1.9k 1.4×	2.1k 1.7×	242 0.4×	1.7k 3.4×	188	5.7k
Dario de Biase Italy	31	1.2k 0.7×	983 0.7×	912 0.7×	158 0.3×	366 0.7×	197	3.2k
Olga B. Ioffe United States	32	796 0.5×	1.0k 0.7×	898 0.7×	663 1.1×	1.1k 2.1×	112	4.3k
Aaron Pollett Canada	33	2.6k 1.5×	1.7k 1.2×	3.9k 3.0×	227 0.4×	1.3k 2.5×	87	6.8k

Countries citing papers authored by Richard W. Tothill

Since Specialization

Citations

This map shows the geographic impact of Richard W. Tothill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard W. Tothill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard W. Tothill more than expected).

Fields of papers citing papers by Richard W. Tothill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard W. Tothill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard W. Tothill. The network helps show where Richard W. Tothill may publish in the future.

Co-authorship network of co-authors of Richard W. Tothill

This figure shows the co-authorship network connecting the top 25 collaborators of Richard W. Tothill. A scholar is included among the top collaborators of Richard W. Tothill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard W. Tothill. Richard W. Tothill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boehm, Emma, Anthony J. Gill, Roderick Clifton‐Bligh, & Richard W. Tothill. (2024). Recent progress in molecular classification of phaeochromocytoma and paraganglioma. Best Practice & Research Clinical Endocrinology & Metabolism. 38(6). 101939–101939. 2 indexed citations

Tothill, Richard W., et al.. (2024). The evolution of molecular management of carcinoma of unknown primary. Current Opinion in Oncology. 36(5). 456–464. 1 indexed citations

Trigos, Anna, Yangyi Zhang, Richard W. Tothill, et al.. (2024). Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins. Genome biology. 25(1). 110–110. 2 indexed citations

Waldeck, Kelly, Carleen Cullinane, Twishi Gulati, et al.. (2023). A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to ¹⁷⁷Lutetium-DOTA-octreotate radionuclide therapy. Theranostics. 13(14). 4745–4761. 6 indexed citations

Wolyniec, Kamil, Clare O’Callaghan, Jessica Sharp, et al.. (2023). A qualitative study of patients with Cancer of Unknown Primary: Perceptions of communication, understanding of diagnosis and genomic testing, and information needs. Psycho-Oncology. 32(4). 589–596. 3 indexed citations

Kong, Grace, Emma Boehm, Owen W.J. Prall, et al.. (2023). Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN). Current Oncology Reports. 25(5). 465–478.

Westphalen, C. Benedikt, Chantal Pauli, Nasséra Chalabi, et al.. (2023). Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO Open. 8(6). 102035–102035. 7 indexed citations

Mileshkin, Linda, Richard W. Tothill, David D.L. Bowtell, et al.. (2022). Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. Supportive Care in Cancer. 30(10). 8217–8229. 4 indexed citations

Zethoven, Magnus, Luciano G. Martelotto, Andrew Pattison, et al.. (2022). Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment. Nature Communications. 13(1). 6262–6262. 26 indexed citations

10.

Weppler, Alison M., Andrew Pattison, Prachi Bhave, et al.. (2020). Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e000700–e000700. 8 indexed citations

11.

Fan, Kaiji, Cathrin Ritter, Paul Nghiem, et al.. (2018). Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. Clinical Cancer Research. 24(23). 5873–5882. 43 indexed citations

12.

Becker, Jürgen C., Andreas Stang, Axel zur Hausen, et al.. (2017). Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunology Immunotherapy. 67(3). 341–351. 73 indexed citations

13.

Wong, Stephen Q., Richard W. Tothill, Sarah‐Jane Dawson, & Rodney J. Hicks. (2017). Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. Journal of Nuclear Medicine. 58(6). 869–870. 3 indexed citations

14.

Hogg, Simon J., Andrea Newbold, Stephin J. Vervoort, et al.. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. 15(9). 2030–2041. 50 indexed citations

15.

Busuttil, Rita A., Joshy George, Richard W. Tothill, et al.. (2014). A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response. Clinical Cancer Research. 20(10). 2761–2772. 65 indexed citations

16.

Mar, Victoria, Stephen Q. Wong, Jason Li, et al.. (2013). BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research. 19(17). 4589–4598. 100 indexed citations

17.

Ryland, Georgina L., Maria Doyle, Samantha E. Boyle, et al.. (2012). MicroRNA Genes and Their Target 3′-Untranslated Regions Are Infrequently Somatically Mutated in Ovarian Cancers. PLoS ONE. 7(4). e35805–e35805. 25 indexed citations

18.

Anglesio, Michael S., Jeremy M. Arnold, Joshy George, et al.. (2008). Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. Molecular Cancer Research. 6(11). 1678–1690. 91 indexed citations

19.

Tothill, Richard W., Anna V. Tinker, Joshy George, et al.. (2008). Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research. 14(16). 5198–5208. 1041 indexed citations breakdown →

20.

Tothill, Richard W., Adam Kowalczyk, Danny Rischin, et al.. (2005). An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. Cancer Research. 65(10). 4031–4040. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact